Opinion: Let the Market Dictate Drug Prices in China

1. China's State Council issued "Several Opinions on Improving the Market-Driven Drug Pricing Mechanism," emphasizing market's decisive role in resource allocation and government's sharpened regulation. It proposes reforms across the pharmaceutical industry's life cycle, distribution, and sectors to boost market dynamics, fair competition, and growth, especially for innovative therapies, aiming for a high-quality sector with affordable, premium drugs for the public [para. 1].

2. Historically, in 2015, the National Development and Reform Commission and six departments mandated market competition for drug transaction prices (excluding narcotics and Class I psychotropics). Paired with a drug review overhaul, this accelerated China's innovative pharmaceutical sector [para. 2].

3. The 2018 National Healthcare Security Administration establishment made insurance payment standards key for guiding prices, leading to reductions for domestic breakthrough therapies in and out of public insurance, benefiting more patients. New guidelines address concerns by aligning efficient markets with proactive government, supporting, protecting, and governing as needed [para. 3].

4. Drug prices act as "batons" directing innovation beyond mere supply-demand signals. Reforms ensure novel treatment costs reflect clinical value, enabling a self-sustaining, evolving ecosystem [para. 4].

5. China's drug innovation has surged from generics to original innovation, now comprising one-third of global innovative drugs in development, with oncology stars. Over 200 innovative drugs approved during the 14th Five-Year Plan; 2025 overseas licensing deals exceeded $130 billion, validating market-led pricing [para. 5].

6. Guidelines provide a blueprint: refine key segment pricing, promote price discovery, keep critical drugs reasonable, strengthen governance, focusing on clinical value and accessibility [para. 6].

7. Top measure: optimize initial pricing for new innovative drugs, distinguishing highly innovative (support high initial prices reflecting risks/investments with stability), modified new drugs, and generics with tailored support [para. 7].

8. Encourages diverse payment methods and rational pricing to enhance accessibility and drugmaker sustainability, positioning China as a global innovation leader [para. 8].

9. Introduces self-assessment for post-launch price adjustments based on real-world outcomes, filtering for true innovation under market scrutiny [para. 9].

10. Uses medical insurance standards to guide prices, balancing fund sustainability, patient welfare, and incentives. Negotiations for registry inclusion consider initial price rationality, affordability, macroeconomics, and value; expands multi-tier insurance and commercial coverage [para. 10].

11. Market-led pricing requires systemic coordination beyond insurance, per 15th Five-Year Plan (2026-2030) outlines for urgent approvals and insurer coverage. Balances innovation subsidies with affordability, curbing failures like high prices, kickbacks, and sales reliance, ensuring accessible, reasonable essential drugs [para. 11].